Cabio Biotech (Wuhan) Dirección

Dirección controles de criterios 3/4

El CEO de Cabio Biotech (Wuhan)'s es Dewei Yi, nombrado en Dec 2015, tiene una permanencia de 8.33 años. posee directamente un 1.39% de las acciones de la empresa, con un valor de CN¥32.80M. La antigüedad media del equipo directivo y de la junta directiva es de 8.3 años y 5.3 años, respectivamente.

Información clave

Dewei Yi

Chief Executive Officer (CEO)

CN¥1.2m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	8.3yrs
Participación del CEO	1.4%
Permanencia media de la dirección	8.3yrs
Promedio de permanencia en la Junta Directiva	5.3yrs

Actualizaciones recientes de la dirección

Recent updates

The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Mar 21

CEO

Dewei Yi (58 yo)

8.3yrs

Permanencia

CN¥1,179,900

Compensación

Mr. Dewei Yi is Chairman of the Board & General Manager of CABIO Biotech(Wuhan) Co., Ltd., since December 2015. From December 1999 he has been the chairman of Wuhan Xiwang Biological Engineering Co., Ltd.;...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Dewei Yi	Chairman of the Board & GM	8.3yrs	CN¥1.18m	1.39% CN¥ 45.8m
Huabiao Wang	CFO & Director	8.3yrs	CN¥999.30k	0.66% CN¥ 21.8m
Huarong Yi	Board Secretary & Deputy GM	2.3yrs	CN¥620.30k	0.089% CN¥ 3.0m
Zhiming Wang	Deputy General Manager	2.3yrs	CN¥794.60k	0.20% CN¥ 6.6m
Min Xiao	Chief Engineer & Application Technology Director	8.3yrs	sin datos	0.059% CN¥ 2.0m

8.3yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 688089 es experimentado (8.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Dewei Yi	Chairman of the Board & GM	8.3yrs	CN¥1.18m	1.39% CN¥ 45.8m
Huabiao Wang	CFO & Director	8.3yrs	CN¥999.30k	0.66% CN¥ 21.8m
Bin Du	Vice Chairman of the Board	8.3yrs	CN¥990.70k	0.58% CN¥ 19.2m
Junyu Wu	Employee Supervisor	8.3yrs	sin datos	0.018% CN¥ 600.9k
Chunyu Zhang	Director	2.3yrs	sin datos	sin datos
Xiangdong Chen	Independent Director	2.3yrs	CN¥80.00k	sin datos
Qi Liu	Independent Director	2.3yrs	CN¥80.00k	sin datos
Jing Chen	Supervisor	2.3yrs	sin datos	sin datos

5.3yrs

Permanencia media

52.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 688089 se considera experimentada (5.3 años de antigüedad promedio).

Cabio Biotech (Wuhan) Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

No independent directors

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.086 in 1Q 2023)

Investor sentiment deteriorates as stock falls 17%

Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Investor sentiment deteriorates as stock falls 20%

Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Price target decreased by 16% to CN¥30.00

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.17 in 2Q 2022)

Cabio Biotech (Wuhan) Co., Ltd. Showcases the New Products and Ready-To-Market Solutions At Vitafoods Europe 2023

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment deteriorates as stock falls 15%

Price target increased by 11% to CN¥56.50

Full year 2022 earnings released: EPS: CN¥0.90 (vs CN¥1.07 in FY 2021)

Investor sentiment improved over the past week

No independent directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.28 in 3Q 2021)

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.28 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.32 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.38 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.21 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.09 (vs CN¥1.31 in FY 2019)

Investor sentiment improved over the past week

CABIO Biotech(Wuhan) Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021

CABIO Biotech(Wuhan) Co., Ltd. (SHSE:688089) entered into an agreement to acquire 11% stake in Zhongke Optics Valley Green Biotechnology Co., Ltd. from Hefei Kejv Hi-tech Co., Ltd. for CNY 10.7 million.

New 90-day low: CN¥34.84

Investor sentiment deteriorated over the past week

New 90-day low: CN¥38.96

New 90-day low: CN¥44.46

New 90-day low: CN¥46.67

First half earnings released

New 90-day high - CN¥59.42

CABIO Biotech(Wuhan) Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad